Over the last decade, several incremental advances have been made in systemic therapy of metastatic breast cancer. Novel endocrine agents, anti-HER2 therapies, targeted therapies, and even cytotoxics have entered routine clinical practice over this time, each offering a different degree of clinical benefit. Standing upon this foundation, we are now facing waves of new information pertaining to tumor immunology and genomics. In this presentation, I will discuss how these new insights might be integrated into our existing knowledge to develop more successful therapeutic strategies.